Eleftheriadis Theodoros, Golphinopoulos Spyridon, Pissas Georgios, Stefanidis Ioannis
Department of Nephrology, University of Thessaly, School of Medicine, Mezourlo Hill, 41110 Larissa, Greece.
J Adv Res. 2017 Sep;8(5):555-560. doi: 10.1016/j.jare.2017.05.001. Epub 2017 May 5.
Today there is plausible evidence both on experimental and epidemiological basis, that hyperuricemia represents a risk factor for the development and progression of chronic kidney disease (CKD). Nevertheless, the role of serum uric acid lowering treatment in CKD is still a matter of serious controversy. Review of randomised controlled trials, suggests that there may be an improvement of renal function with allopurinol treatment in CKD stage 3-5. However, these studies have included a relatively limited number of participants and provide insufficient information on adverse events and on the incidence of the end stage renal disease. Therefore, before adequately powered randomised, placebo-controlled trials are completed we cannot recommend treating asymptomatic hyperuricemia in patients with CKD.
如今，基于实验和流行病学依据，有看似合理的证据表明高尿酸血症是慢性肾脏病（CKD）发生和进展的一个危险因素。然而，血清尿酸降低治疗在CKD中的作用仍是一个存在严重争议的问题。对随机对照试验的综述表明，在3 - 5期CKD患者中，使用别嘌醇治疗可能会改善肾功能。然而，这些研究纳入的参与者数量相对有限，并且在不良事件和终末期肾病发生率方面提供的信息不足。因此，在完成足够样本量的随机、安慰剂对照试验之前，我们不能建议对CKD患者的无症状高尿酸血症进行治疗。
